Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
According to the paper, artificial intelligence addresses a core weakness in Parkinson’s care: reliance on subjective ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Job cuts include the company's U ...
Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Akinesia is a condition where you cannot make voluntary movements, ...
Scientists report that specific RNA patterns in blood may detect Parkinson’s disease early, opening a window for earlier care ...
Some Parkinson’s patients may experience strange symptoms, like smell loss and sleep disorders, decades before diagnosis.